Bacterial Infections
Conditions
Brief summary
This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy adult subjects. Male or female subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Detailed description
This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy adult subjects. Male or female subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study. Up to 5 cohorts of 8 subjects each (up to a total of 40 subjects) will be enrolled. Subjects in each cohort will be randomized 6:2 to receive multiple oral doses of TP 271 or placebo. Every effort will be made to dose all subjects in a cohort on the same day. Doses of study drug will be administered orally either once daily in the morning or twice daily in the morning and evening from Days 1 to 7. In all subjects, the morning dose will be administered following an overnight fast (minimum 8 hours) of food and all beverages, except for water. For subjects in Cohorts D and E only, the evening dose will be administered following a minimum 3-hour fast of food and all beverages, except for water. Fasting in all cohorts will continue for at least 2 hours following each study drug administration. During the Screening Period (within 28 days prior to the subject receiving study drug), each subject will be assessed for eligibility. Each subject must sign and date an ICF prior to undergoing any study-related procedures.
Interventions
DRUGTP-271
multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Tetraphase Pharmaceuticals, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Intervention model description
Up to 5 cohorts of 8 subjects each will be enrolled. Subjects in each cohort will be randomized 6:2 to receive multiple oral doses of TP 271 at 1 of 5 ascending doses of TP-271 or placebo once or twice daily for 7 days, as shown in the table below. Every effort will be made to dose all subjects in a cohort on the same day. Proposed Oral Doses of Study Drug by Dose Cohort Cohort Dose Regimen Proposed Oral Dose A Once daily 50 mg TP-271 q24 (n = 6) or matching placebo (n = 2) B Once daily 100 mg TP-271 q24 (n = 6) or matching placebo (n = 2) C Once daily 200 mg TP-271 q24 (n = 6) or matching placebo (n = 2) D Once daily 300 mg TP-271 q24 (n = 6) or matching placebo (n = 2) E Once daily 400 mg TP-271 q24 (n = 6) or matching placebo (n = 2) Abbreviations: q24 = every 24 hours.
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Be within the age range of 18 to 50 years, inclusive, at the time of Screening 2. Voluntarily sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved ICF to participate in the study after all relevant aspects of the study have been explained to and discussed with the subject and before undergoing any study-related procedures 3. Have a body mass index (BMI) ≥18.0 and ≤33.0 kg/m2 4. Have a negative history of and negative screening results for human immunodeficiency virus (HIV) types 1 and 2 and hepatitis B and C 5. Have the ability to communicate with the study unit staff in a manner sufficient to carry out all protocol procedures as described 6. Female subjects must be of non-childbearing potential, either 1-year postmenopausal or surgically sterile (i.e., bilateral oophorectomy, bilateral tubal ligation, or complete hysterectomy) 7. Male subjects must be willing and able to use a barrier method of contraception or practice abstinence (including male subjects who had a vasectomy) from dosing to 90 days after final administration of the study drug
Exclusion criteria
1. History and/or presence of any clinically significant disease or disorder, such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal, endocrine, psychiatric or mental disease or disorder, or mental or legal incapacitation, which, in the opinion of the PI, may either put the subject at risk due to participation in the study, influence the results of the study, or influence the subject's ability to participate in the study 2. Clinical laboratory values that fall outside of the eligibility range specified in Appendix D are exclusionary; for clinical laboratory values that are not included in Appendix D, values outside of the reference range are exclusionary, except for those parameters listed in Table 4). Table 4 Acceptable Out-of-Range Clinical Laboratory Values Low Chemistry Values: Bicarbonate (a) Chloride GGT HDL cholesterol LDH LDL cholesterol Phosphorus High Chemistry Values: Chloride HDL cholesterol LDL cholesterol Phosphorus Triglycerides Out-of-Range Urinalysis Values; High or low specific gravity Cloudy Mucus Crystals Ketones (b) Hyaline casts High or low pH Urobilinogen (c) Out of Range Hematology Values; High hematocrit Basophils Monocytes MCV MCH MCHC RBC a Bicarbonate \>18 mEq/L. b Acceptable only when the concurrent blood glucose is normal. c Measured when monitoring the serum bilirubin concentration. Abbreviations: GGT = gamma-glutamyltransferase; HDL = high-density lipoprotein; LDH = lactate dehydrogenase; LDL = low-density lipoprotein; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; RBC = red blood cell. 3. Known allergy to tetracycline antibiotics or any of the excipients in TP 271 4. Clinically significant abnormality on a 12-lead ECG, which includes the following: * Rhythm other than sinus * Corrected QT interval using Fridericia's formula (QTcF) \>450 msec * Evidence of second- or third-degree atrioventricular (AV) block * Pathological Q-waves (defined as a Q-wave \>40 msec or depth \>0.4 to 0.5 mV) * Evidence of ventricular pre-excitation * Evidence of complete left bundle branch block (BBB), right BBB, or incomplete left BBB * Intraventricular conduction delay with QRS duration \>120 msec * ST segment abnormalities, unless judged by the PI to be nonpathologic 5. History of seizures 6. History within 3 years of a positive result on a urine screen for drugs of abuse or a positive result on a urine screen at Screening for any of the following drugs of abuse: tetrahydrocannabinols, cocaine, opioids, phencyclidines, amphetamines, benzodiazepines, barbiturates, and cotinine 7. Use of tobacco, nicotine, or nicotine-replacement products within 3 months prior to initial administration of study drug to the EOS Visit 8. Typical weekly alcohol consumption of 7 or more alcoholic drinks, where 1 alcoholic drink is defined as 1 glass of beer (approximately 10 to 12 oz), 1 can of beer (12 oz), 1 glass of wine (approximately 4 to 5 oz), or distilled spirits (approximately 1 oz or 30 mL of liquor) 9. Alcohol consumption within 48 hours prior to admission 10. Participation in a clinical study within 10 half-lives of the prior study treatment or within the previous 3 months (if the half-life of investigational agent is unknown) prior to initial administration of study drug or planned participation in another clinical study concurrent with the present study 11. History of difficulty donating blood or poor venous access 12. Recent blood donation (1 unit or approximately 525 mL) within 1 month prior to receiving study drug or plans to donate prior to receiving study drug or during the clinical study 13. Use of any prescription or nonprescription medication, including vitamins or herbal medications, vaccination, or immunization within 7 days or 5 half-lives (if known), whichever is longer, prior to initial administration of study drug, with the following exceptions: medications used to treat an AE are permitted, and the use of acetaminophen, naproxen, and ibuprofen is permitted, except for within 24 hours prior to dosing 14. Male subjects who donate or plan to donate sperm during the study or within 90 days after final administration of the study drug 15. Unwillingness or inability to follow the procedures outlined in the clinical study protocol 16. Previous participation in another TP-271 study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vital Signs including body temperature | Day -1 to the end of study visit, Day 21 | Changes in body temperature |
| Adverse Events | From the time of signing of the informed consent form throughout study completion (approximately 39 days) | Incidence, intensity, and type of adverse events. |
| A Directed Physical Examination including chest/respiratory | Day -1 to the End of Study visit, Day 21 | changes in physical examination findings for chest/respiratory |
| A Directed Physical Examination including heart/cardiovascular | Day -1 to the End of study visit, Day 21 | Changes in Physical Examination including heart/cardiovascular |
| Vital Signs including Pulse Rate | Day -1 to the End of study visit, Day 21 | Changes in Pulse Rate |
| Vital Signs including respiration rate | Day -1 to the End of study visit, Day 21 | Changes in respiration rate |
| Vital Signs including blood pressure | Day -1 to the End of study visit, Day 21 | Changes in blood pressure |
| ECG measurements including PR interval | Day -1 to the End of study visit, Day 21 | Changes in PR interval \> or=20 |
| ECG measurements including QRS interval | Day -1 to the end of study visit, Day 21 | Changes in QRS interval\> or=10 |
| ECG measurements including QTcF interval | Day -1 to the end of study visit, Day 21 | Changes in QTcF interval 30 to 60, \> or =60 |
| Safety Laboratory results including clinical chemistry | Day -1 to the End of study visit, Day 21 | Changes in safety laboratory results including clinical chemistry |
| Safety Laboratory results including electrolytes | Day -1 to the End of study visit, Day 21 | Changes in safety laboratory results including electrolytes |
| Safety Laboratory results including hematology | Day -1 to the End of study visit, Day 21 | Changes in safety laboratory results including hematology |
| Safety Laboratory results including blood glucose | Day -1 to the End of study visit, Day 21 | Changes in Safety laboratory results including glucose |
| Safety Laboratory results including coagulation | Day -1 to the End of study visit, Day 21 | Changes in Safety Laboratory results including coagulation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma concentrations | Days 1-7 | Plasma concentrations of TP-271 and its C-4 epimer TP-9555 for PK analysis |
| Urine pharmacokinetics | Days 1-7 | Urine concentrations of TP-271 and it's C-4 epimer, TP-9555 |
| PK parameters - Cmax | Days 1-7 | PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Cmax (the maximum observed plasma concentration) |
| PK parameters- Tmax | Days 1-7 | PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Tmax |
| PK parameters AUC (0-last) | Days 1-7 | Area under the concentration versus time curve (AUC) from time zero to the last measured time point |
| PK parameters - AUC (0-inf) | Days 1-7 | PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC (0-inf) (The area under the concentration vs time curve from time zero extrapolated to infinity) |
| PK parameters- AUC% extrapolated | Days 1-7 | PL parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC% extrapolated (the percentage of AUC 90-inf) accounted for by extrapolation) |
| PK parameters - AUC (0-24) | Days 1-7 | AUC from time zero to 24 hours (AUC 0-24) |
| PK parameters - Lambda-z | Days 1-7 | PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Lambda-z (Slope of the regression line passing through the apparent elimination phase in a concentration vs time plot) |
| PK parameters - CL | Days 1-7 | PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for CL (Clearance: the volume of plasma cleared per unit time) |
| PK parameters - Vd | Days 1-7 | PK parameters will be calculated using the apparent volume of distribution following oral dosing |
| PK parameters -T 1/2el | Days 1-7 | PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for T1/2el (The elimination half-life) |
Countries
United States
Outcome results
None listed